These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 21119522)

  • 21. A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia.
    Bhanji NH; Chouinard G; Margolese HC
    Eur Neuropsychopharmacol; 2004 Mar; 14(2):87-92. PubMed ID: 15013023
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Health resource utilization associated with switching to risperidone long-acting injection.
    Young CL; Taylor DM
    Acta Psychiatr Scand; 2006 Jul; 114(1):14-20. PubMed ID: 16774656
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risperidone long-acting injection in practice - more questions than answers?
    Taylor D
    Acta Psychiatr Scand; 2006 Jul; 114(1):1-2. PubMed ID: 16774654
    [No Abstract]   [Full Text] [Related]  

  • 24. Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder.
    Lasser R; Bossie CA; Gharabawi G; Eerdekens M; Nasrallah HA
    J Affect Disord; 2004 Dec; 83(2-3):263-75. PubMed ID: 15555724
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risperidone long-acting injection: a prospective 3-year analysis of its use in clinical practice.
    Taylor DM; Fischetti C; Sparshatt A; Thomas A; Bishara D; Cornelius V
    J Clin Psychiatry; 2009 Feb; 70(2):196-200. PubMed ID: 19026261
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
    Houthoofd SA; Morrens M; Sabbe BG
    Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable.
    Gharabawi G; Bossie C; Turkoz I; Kujawa M; Mahmoud R; Simpson G
    J Nerv Ment Dis; 2007 Dec; 195(12):976-82. PubMed ID: 18091190
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in Huntington's disease.
    Duff K; Beglinger LJ; O'Rourke ME; Nopoulos P; Paulson HL; Paulsen JS
    Ann Clin Psychiatry; 2008; 20(1):1-3. PubMed ID: 18297579
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic drug monitoring of patients on risperidone depot.
    Nesvåg R; Tanum L
    Nord J Psychiatry; 2005; 59(1):51-5. PubMed ID: 16195099
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: efficacy, quality of life and functional outcome.
    Lloyd K; Latif MA; Simpson S; Shrestha KL
    Hum Psychopharmacol; 2010 Apr; 25(3):243-52. PubMed ID: 20373476
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.
    Kane JM; Leucht S; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2003; 64 Suppl 12():5-19. PubMed ID: 14640142
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder.
    Lasser RA; Bossie CA; Zhu Y; Gharabawi G; Eerdekens M; Davidson M
    Int J Geriatr Psychiatry; 2004 Sep; 19(9):898-905. PubMed ID: 15352149
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness.
    Keith S
    Expert Rev Neurother; 2009 Jan; 9(1):9-31. PubMed ID: 19102665
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New for old? Risperidone long-acting injection in older patients.
    Hudson-Jessop P; Hughes B; Brinkley N
    Australas Psychiatry; 2007 Dec; 15(6):461-4. PubMed ID: 17999255
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risperidone long-acting therapy in stable patients with recently diagnosed schizophrenia.
    Macfadden W; Bossie CA; Turkoz I; Haskins JT
    Int Clin Psychopharmacol; 2010 Mar; 25(2):75-82. PubMed ID: 20101185
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacologic approaches to the treatment of Huntington's disease.
    Venuto CS; McGarry A; Ma Q; Kieburtz K
    Mov Disord; 2012 Jan; 27(1):31-41. PubMed ID: 21997232
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of psychotic and behavioral symptoms with clozapine, aripiprazole, and reboxetine in a patient with Huntington's disease.
    Edlinger M; Seppi K; Fleischhacker W; Hofer A
    Int Clin Psychopharmacol; 2013 Jul; 28(4):214-6. PubMed ID: 23652781
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Possible long-acting risperidone-induced hypothermia precipitating phenytoin toxicity in an elderly patient.
    Brandon Bookstaver P; Miller AD
    J Clin Pharm Ther; 2011 Jun; 36(3):426-9. PubMed ID: 21545623
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risperidone in chorea and psychosis of Huntington's disease.
    Erdemoglu AK; Boratav C
    Eur J Neurol; 2002 Mar; 9(2):182-3. PubMed ID: 11882064
    [No Abstract]   [Full Text] [Related]  

  • 40. Risperidone long-acting injection: a brief overview.
    Lemon M
    S D J Med; 2004 May; 57(5):171-2. PubMed ID: 15181859
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.